Featured Companies

Amedica Corporation, AMDA, Profile, Summary

PDF Print E-mail

Amedica Corporation, AMDA, Profile, Summary


 

Amedica Corporation, AMDA, is a commercial biomaterial company. The Company is focused on using its silicon nitride technology platform to develop, manufacture and sell a range of medical devices. The Company markets spinal fusion products and are developing products for use in total hip and knee joint replacements.

 

Biomaterials are synthetic or natural materials available in a variety of forms that are used in virtually every medical specialty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States and Europe for use in the cervical and thoracolumbar areas of the spine. In addition, to its silicon nitride-based spinal fusion products, it markets a complementary line of non-silicon nitride spinal fusion products which allows providing surgeons and hospitals with a range of products. The Company produces its silicon nitride advanced ceramic in four forms: a fully dense, load-bearing solid, referred to as MC2; a porous bone-like cancellous structured form, referred to as CSC; a composite incorporating both its solid MC2 material and its porous CSC material intended to promote an environment for bone growth; and a coating for application onto other biomaterials.

 

The Company competes with Medtronic, Inc.; DePuy Synthes Companies, a group of Johnson & Johnson companies; Stryker Corporation; Biomet, Inc.; Zimmer Holdings, Inc.; Smith & Nephew plc; Aesculap Inc; CeramTec, Kyocera, and CoorTek, Inc.

 

OSTEOPROMOTIVE: DELIVERS ENHANCED OSTEOGENIC RESPONSE

  • Enhanced osteopromotion: The surface chemistry and nanostructure topography of Si3N4 provides an optimal environment for stimulation of osteoprogenitor cells to differentiate into osteoblasts.

  • Greater protein adsorption: Si3N4 demonstrates significantly greater protein adsorption (fibronectin, laminin and vitronectin) in comparison to PEEK and titanium. (1)

  • Greater new bone formation: Si3N4 implants demonstrate greater new bone formation at 3, 7, 14 and 90 days compared to PEEK and titanium in in vivo study; regenerated bone associated with Si3N4 implants is 2 to 3 times that of PEEK and titanium implants at 3 months after surgery.(2)

  • Increased osteointegration: Si3N4 implants demonstrate increased osteointegration at 3, 7, 14 and 90 days compared to PEEK and titanium in in vivo studies; percent of bone at Si3N4 implant interface is 2 to 6 times that of PEEK and titanium implants at 3 months after surgery.(2)

DEMONSTRATED ANTI-INFECTIVE PROPERTIES

  • Superior antibacterial function: Si3N4 inhibits biofilm formation and bacterial colonization. Si3N4 demonstrates significantly lower biofilm formation at 4, 24, 48 and 72 hours as compared to PEEK and titanium; live bacteria (S. epidermidis, S. aureus, P. aeruginosa, E. coli and Enterococcus) associated with Si3N4 implants are 8 to 30 times lower than PEEK and titanium.(1)

  • Demonstrated bacteriostatic agent: In in vivo studies, no infection is observed with bacteria-inoculated Si3N4 implants at 3 months, whereas both PEEK and titanium implants maintain a septic state. Si3N4 demonstrates this property even in the absence of antibiotics.(2)

EXCELLENT IMAGING PROPERTIES

  • Compatible with all imaging modalities: Si3N4 implants are semi-radiolucent with clearly visible boundaries, and produce no distortion under MRI and no scattering under CT; this enables an exact view of the implant for precise intraoperative placement and postoperative fusion assessment.

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

 

SDIG, Station Digital, Profile, Summary

PDF Print E-mail

 

StationDigital Corporation

Multimedia Digital Broadcasting

 

StationDigital, SDIG, is a multimedia digital broadcast company that offers free music streaming of over 30 million songs. StationDigital features both genre-based and artist-based music discovery stations to suit an endless variety of musical tastes, and a personal recommendation service to its more than 2.4 million unique listeners – all available both online and through its iOS and Andriod mobile apps. StationDigital’s users can customize their listening experience by selecting playlists and stations based on themes, interests and location, as well as favorite artists, songs, genre, and by providing feedback on the music they hear.

 

StationDigital is the first truly next generation digital media broadcast platform.

 

StationDigital’s primary identity is as a sophisticated pure play music discovery Internet radio service, offering a competitive, state of the art product to capture market share in the Internet radio space. The Company has a unique, industry first value proposition - the StationDigital Listener Rewards Program, where all registered users earn listener rewards

points:

 

>  Every time users listen to StationDigital, either on the web or through their mobile apps

>  Every time users share StationDigital with friends through social media

 

Key Features:

 

Social features and network effect – feedback on music, share music with friends and family, recommendations, post favorites on timeline, and earn reward points. Users can gain followers and build their own music social network of friends and fans.

 

Unique personalization of music to user’s taste – choose genre, artist, decade and ability to narrow search to a very specific target to get to songs faster. Features include ability to adjust music preferences, create a station playlist, and leverage songs from community of users.

 

Music discovery – with over 30 million songs and hundreds of stations providing a wide variety of categories and genres, users are always able to discover something new. Add/remove stations with one touch, smooth intuitive song catalog, 30 million songs, choose decade, genre, artist.

 

 

 

StationDigital will become the first agnostic, multimedia, global broadcast platform – available on any device, from anywhere, at anytime.

 

Investment Highlights

 

Opportunity to invest in an innovative, early stage next generation multimedia broadcast company with a unique and differentiated service and business model aimed at a rapidly growing and large market opportunity

 

The Company’s music streaming service has over 30 million songs for its 2.4 million users that offers customized listening, music discovery, a personal recommendation engine, a value-added social layer, and e-commerce platform

 

Key competitive differentiation factors are its unique listener rewards program/online store and wide variety of entertainment content options beyond music

 

Music streaming industry is still in its early stages and is experiencing rapid growth and market share capture from a large addressable $15 billion US radio market

 

Our valuation analysis results in a target price of $0.81 per share which represents significant upside of over 2 times the current stock price

 

see Investment Thesis click here

 

 

VALUATION

 

Starting with Pandora’s market cap per user of $38.63 and then applying a 65% discount to account for Pandora’s first mover advantage, dominant competitive position, and execution track record, we arrived at a market cap per user of $13.52. Based on management’s aggressive marketing plan, it can be estimated that StationDigital will have approximately 5 million monthly active users by the end of 2016. Applying this $13.52 market cap per user to 5 million monthly active user results in a StationDigital target market capitalization of $67.6 million or price per share of $0.81.

 

Our target price of $0.81 is over 2.0 times the current share price of $0.40 providing significant upside price potential while also being only 35% above the Company’s recent high of $0.60 last October.

 

learn more about this great opportunity, download the full report now! click here

visit the company website www.StationDigitial.com

Start Enjoying the Music You Love!

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.commusic, music streaming, top 10 tracks, top 100 tracks, top 10 songs, top 100 songs, top 40 songs, top country music, top hip hop artists, top performers, top country singers, top female vocalists, top male singers, top on the bill board charts,free music, free downloads, itunes, google music, yahoo music, like spotify, better than pandora, more personal than sound could.

 

 

Aethlon Medical, AEMD, Profile, Summary

PDF Print E-mail

Aethlon Medical, AEMD, Profile, Summary


 

Aethlon Medical (AEMD) is developing innovative medical devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon’s ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C.

 

HER2 Protein and Breast Cancer

Breast cancer is the most common form of cancer in women, accounting for 20% of cancer deaths with approximately 180,000 women diagnosed annually in the United States (Merrill, R. M., and A. Sloan. 2011. Risk-adjusted female breast cancer incidence rates in the United States. Cancer Epidemiol.). Over-expression of the human epidermal growth factor receptor 2 (HER2; ErbB2) gene occurs in approximately 25% of breast cancers and has been linked to poor prognosis (Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182). HER2 is a receptor tyrosine kinase, member of the EGF receptor family, which possesses proliferative and anti-apoptotic activities.

 

The standard of treatment for women diagnosed with HER2+ breast cancer includes the humanized monoclonal antibody trastuzumab (marketed as Herceptin®) directed against the extracellular domain of HER2. Trastuzumab binding to HER2 mediates direct growthinhibition of tumor cells and induces antibody-dependent cell cytotoxicity (ADCC), a major anti-cancer mechanism by which natural killer (NK) cells lyse antibody-coated tumor cells (Nahta, R., D. Yu, M. C. Hung, G. N. Hortobagyi, and F. J. Esteva. 2006. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280).

 

In patients with metastatic breast cancer undergoing chemotherapy, treatment with trastuzumab augments overall response rates and increases median survival time by 25% (Baselga, J. 2001. Clinical trials of Herceptin® (trastuzumab). Eur J Cancer 37 Suppl 1:18-24). However, response rates to trastuzumab range from 12% to 34% with median duration of 9 months due to development of resistance. Despite co-treatment with other HER2 targeting therapies (e.g. the tyrosine kinase inhibitor lapatinib) and chemotherapy, patients with metastatic breast cancer experience a limited duration of benefit; therefore, novel treatment strategies that act synergistically or overcome drug resistance are urgently needed (Sachdev, J. C., and M. Jahanzeb. 2011. Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer.

 

The Evolution of Therapeutic Filtration to Improve Hepatitis-C Virus (HCV) Treatment Outcomes

 

Therapeutic filtration of HCV from the entire circulatory system with a medical device has been clinically demonstrated to improve treatment outcomes when administered at the outset of standard of care (SOC) drug therapy. This summary overview, which includes an introduction to the Aethlon Hemopurifier®, is for informational purposes only.

 

About HCV Infection

The U.S. National Institutes of Health (NIH) reports an estimated 180 million people worldwide are afflicted with chronic HCV infection. Of people infected, 55 to 85% of will develop chronic infection, and 75% of those will develop chronic liver disease. Standard of care (SOC) drug therapy is represented by a two drug combination of interferon and ribavirin. The primary goal of SOC drug therapy is the achievement of a sustained virologic response (SVR), defined as undetectable viral load six months after completion of SOC drug therapy. According to the NIH, 15-25% of HCV infected patients will recover

completely.

 

SOC Drug Therapy Outcomes

The largest study of HCV infected individuals pursuing 48-week SOC drug

therapy was a study of 4,469 genotype 1 patients published by McHutchison in The New England Journal of Medicine in August of 2009.

31% (1,399 of 4,469) of patients screened for participation were excluded from the study.

54% (1,654 of 3,070) of treated patients completed the SOC treatment regimen.

39.6% (1,215 of 3,070) of treated patients who completed SOC therapy

achieved a SVR.

27% (1,215 of 4,469) of the total patients screened for study participation

achieved a SVR.

No data recorded for patients who may have relapsed after achieving a SVR.

 

The Hemopurifier®

The first medical device to selectively remove HCV and related immunosuppressive proteins from circulation. A Study of the Hemopurifier® + SOC Drug Therapy is Now Underway

 

Patient enrollment has been initiated at the Medanta Medicity Institute in India - www.medanta.org

Additional details can be accessed from the Clinical Trials Registry - India (CTRI) link: http://ctri.nic.in/clinicaltrials/index.jsp

Up to 30 patients / up to 6 treatments in first 3 days of SOC

Early clinical endpoints include:

Immediate Virologic Response (IVR)

Rapid Virologic Response (RVR)

Early Virologic Response (EVR)

 

The Hemopurifier® Other Selected Quick Facts

 

70 human treatment experiences administered to date

An Investigation Device Exemption (IDE) to initiate U.S. studies has been filed with FDA

Substantial viral load reductions have also been observed in a human HIV study performed in the absence of antiviral drugs

GMP manufacturing has been established in an FDA approved facility

The Hemopurifier® has proven broad-spectrum capabilities against viral bioterror and pandemic threats

The device has been discovered to capture tumor-secreted exosomes known to suppress the immune system of cancer patients

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

 

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

ALS, Hepatitis C, Traumatic Brain Injury, Blood Sepsis,breast cancer,HIV,HPV,HCV,SOC, dialysis,DOD,UNT,USPTO, NFL,SOCCOR,MILITARY,COMBAT MISSIONS,PTSD, Ebola


 

 

 

 

Last Updated - Thursday, 26 February 2015
 

Premier Biomedical, BIEI, Profile, Summary

PDF Print E-mail

 

Premier Biomedical | BIEI | Profile | Summary

 

Premier Biomedical (BIEI) is a research-based company that has acquired exclusive licenses for patent-pending medications and medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses: ALS, Traumatic Brain Injury, Multiple Sclerosis, Clinical Depression, Alzheimer’s Disease, Blood Sepsis, and Cancer. The company is in the process of developing targeted medicines and procedures and will prove out their superior efficacy in addressing these diseases and others through laboratory, hospital, and actual patient applications. At the anticipated successful conclusion of the clinical trials, contact will be established with the leading worldwide pharmaceutical firms to establish the right to market and distribute Premier Biomedical’s technology products and procedures.
 

INVESTMENT HIGHLIGHTS

· The Company’s proprietary Sequential Dialysis Technique and patented candidate drug Feldetrex are expected to provide superior efficacy versus existing medications in treating a large number of the most fatal diseases

o Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis, and Cancer

 

· The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense

o Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner

o Positive results in animal testing for the Sequential Dialysis Technique treatment of cancer

o Initiation of two clinical trials including a trial for Feldetrex and a trial of the Sequential Dialysis Technique
 

EXECUTIVE SUMMARY

· Premier Biomedical is a research-based company that intends to discover and develop medical treatments targeting the treatment of:  Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis, and Cancer

 

· The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects

o Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects

o Targets cancer, Alzheimer’s disease, Multiple Sclerosis, ALS, blood sepsis, and Traumatic Brain Injury – collectively over $700 billion market opportunity
 

· Developed a proprietary drug candidate Feldetrex as a potential treatment for Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury

o Expected to deliver significant relief to patients, while presenting fewer side effects than other alternate medications

o The Company was recently granted two US patents for this drug candidate

oThe annual market size of all proposed market segments for Feldetrex is $16 billion
 

· The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense

o Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner

o Positive results in animal testing for the Sequential Dialysis Technique treatment of cancer

o Initiation of two clinical trials including a trial for Feldetrex and a trial of the Sequential Dialysis Technique

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Want to get your company featured? or have questions/comments, please don't hesitate to contact the Editor. editor [@] OTCking.com

Last Updated - Sunday, 02 November 2014
 
Page 4 of 21
OTCKing
Sound View Plaza, 7th Floor
1266 E Main St.
Stamford, CT 06902, US
FREE! Premium Membership. DON'T miss the next Exclusive Alert! Become
a MEMBER Today!

Look for exclusive alerts

The Score Card

ARTI.PK* 0.0021   + 52%
EHSK.PK 0.17   + 108%
HGSI 3.35   + 226%
INCC.OB 0.01   + 346%
JGPK.OB 0.18   + 116%
STZU.PK 0.12   + 41%
TTEG.OB 0.36   + 156%
Look us up ON
these and other
PREMIER FINANCIALweb sites.
Bloomberg
FREE! Premium Membership. DON'T miss the next Exclusive Alert! Become a MEMBER Today!